Agilent Technologies, Inc. · NYSE:A
Agilent Technologies — Q4 2018 Earnings Presentation
10 slides from Agilent Technologies's earnings presentation, 2018
Slide 1: Agilent Technologies Q4'18 Results Presentation
Agilent Technologies Q4'18 Results Presentation
Slide 2: Safe Harbor
Safe Harbor This presentation contains forward-looking statements (including, without limitation, information and future guidance on the company’s goals, priorities, revenues, operating profit and operating margin, expected cash flow, growth opportunities, customer service and innovation plans, new
Slide 3: Agilent Results Q4'18 and FY18
Agilent Results Q4’18 and FY18 Scale and leading technology across Analytical Laboratories and Clinical & Dx markets Q4'18 Financial Metrics FY18 Highlights • Revenues: $1.29B, +8.5% y/y core(1)(2),+8.8% • Revenues: Core revenue growth of 7.1%. reported (+1.5% M&A, -1.2% FX). • Operating Margin: 22.
Slide 4: Life Sciences & Applied Markets Group (LSAG)
Life Sciences & Applied Markets Group (LSAG) • Core revenue growth driven by robust growth in Instrumentation and Informatics for Analytical Laboratories Environmental/Forensics and Pharma. LC/MS, LC, Cell Analysis and ICP/MS demand led results. • Operating Margin for the quarter was 25.9%(1)(2), up
Slide 5: Agilent Cross Lab Group (ACG)
Agilent Cross Lab Group (ACG) • Continued strong revenue performance across Analytical Laboratory Consumables and Services both services and consumables. China led with high- teens growth. • Operating Margin in the quarter was 24.7%(1)(2), up 180 bps versus last year. • Acquired the Agilent-related
Slide 6: Diagnostics and Genomics Group (DGG)
Diagnostics and Genomics Group (DGG) Pathology, Genomics, and • Revenue growth led by demand in NASD, target Nucleic Acid Manufacturing enrichment and microarray products. • Operating Margin for the quarter was 23.3%(1)(2), up 180 bps versus last year. • Agilent has been selected by Unilabs, one of
Slide 7: Growth in a $52B Market – Q4'18 Results by End Market
Growth in a $52B Market – Q4'18 Results by End Market Gains highlighted by robust Environmental/Forensics and Pharma Analytical Laboratory End Markets ▪ Q4'18 revenues: +9% y/y on core(2) basis ▪ Pharma & Biotech: Up 14% with broad-based strength across all segments and regions. Growth balanced betw
Slide 8: Profitable Growth Plan
Agilent Profitable Growth Plan Recent Actions ▪ Delivering on “Agile Agilent” Initiatives • Multi-year program to increase efficiency and customer focus. • Adjusted 0perating Margin expanded 190 bps in Q4 over prior year. ▪ Portfolio Investments and “Go-to-Market” Capability • Acquired ACEA Bioscien
Slide 9: Strategy to Win
Agilent Strategy to Win Creating shareholder value ▪ Above Market Growth • Innovative, highly differentiated new products and solutions • Win enterprise lab-wide services & consumables - CrossLab • Accelerate bio-pharma penetration • Drive adoption of clinical genomics applications ▪ Aggressively ex
Slide 10: Q1'19 and FY19 Guidance and Forward-looking Considerations
Q1’19 and FY19 Guidance and Forward-looking Considerations Based on October 31, 2018 Exchange Rates Q1'19 Guidance (1) FY'19 Guidance (1) Low-End High End Low-End High End Net Revenue (M$) $1,265 $1,280 Net Revenue (M$) $5,130 $5,170 Y/Y Core Revenue Growth (2) 4.5% 5.5% Y/Y Core Revenue Growth (2)